Phase I evaluation of safety of intravenous infusion of a pathotropic vector bearing a cytocidal cyclin G1 construct (Rexin-G) as intervention for locally advanced and metastatic pancreatic cancer refractory to standard chemotherapy

Trial Profile

Phase I evaluation of safety of intravenous infusion of a pathotropic vector bearing a cytocidal cyclin G1 construct (Rexin-G) as intervention for locally advanced and metastatic pancreatic cancer refractory to standard chemotherapy

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Jan 2017

At a glance

  • Drugs Rexin-G (Primary)
  • Indications Pancreatic cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Epeius Biotechnologies Corporation
  • Most Recent Events

    • 13 Feb 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top